TKNO Alpha Teknova Inc.

Biotech Analyst Ratings

Latest News

1. 11 May 2022 Teknova Reports First Quarter 2022 Financial Results

   First quarter 2022 total revenue was $11.1 million, up 23% year-over-year
   Excluding Sample Transport revenue, first quarter 2022 total revenue was $11.1 million, up 37% year-over-year
   Strong cash position of $76.5 million supports investment in growth strategy

   HOLLISTER, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced financial results for the first quarter ended March 31, 2022.

   "2022 is off to an excellent start. Order demand remains strong, and we achieved a record revenue quarter," said Stephen Gunstream, President and CEO of…

   View Full Article
2. 04 May 2022 Teknova to Report First Quarter 2022 Financial Results on May 11, 2022

   HOLLISTER, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2022, on Wednesday, May 11, 2022, following the close of market.
   

   Teknova will host a webcast and conference call on Wednesday, May 11, 2022, beginning at 4:30 p.m. ET. Participants can access the live webcast on the Investor Relations section of the Teknova website and at this link: https://edge.media-server.com/mmc/p/6nk6u95b. The conference call can also be accessed by dialing +1 877-312-1451…

   View Full Article
3. 15 March 2022 Teknova Reports Fourth Quarter and Full Year 2021 Financial Results

        Full year 2021 total revenue was $36.9 million, up 18% year-over-year
   Excluding Sample Transport revenue of $1.5 million, full year 2021 total revenue was $35.4 million, up 31% year-over-year
   Company provides 2022 revenue guidance of $44-$48 million

   HOLLISTER, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced financial results for the fourth quarter and the full year ended December 31, 2021.

   "We had solid fourth quarter revenue and a great finish to a year in which we made meaningful progress against our strategic priorities…

   View Full Article
4. 02 March 2022 Teknova to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022

   HOLLISTER, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year 2021 on Tuesday, March 15, 2022, following the close of market.
   

   Teknova will host a webcast and conference call on Tuesday, March 15, beginning at 4:30 p.m. ET. Participants can access the live webcast on the Investor Relations section of the Teknova website and at this link: https://edge.media-server.com/mmc/p/6tqmpjbi. The conference call can also be accessed by dialing +1 877-312-1451…

   View Full Article
5. 28 February 2022 Teknova Announces Preliminary Revenue of $10.0 to $10.1 Million for the Fourth Quarter 2021

   HOLLISTER, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced preliminary unaudited revenue for the fourth quarter ended December 31, 2021, of $10.0 to $10.1 million, including Sample Transport of approximately $0.5 million.   Excluding Sample Transport, total unaudited revenue for the fourth quarter ended December 31, 2021, was $9.5 to $9.6 million.
   

   "Our team delivered an outstanding finish to 2021, resulting in revenue growth of 31%, excluding Sample Transport, above our long-term target of 25% growth," said Stephen Gunstream, President…

   View Full Article